17 Capital Partners’s AbbVie ABBV Stock Holding History

17 Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$306K	Sell	1,218 -58	-5%	-$12.5K	0.14%	155
2026 Q1	$278K	Buy	1,276 +227	+22%	+$50.4K	0.14%	158
2025 Q4	$240K	Sell	1,049 -29	-3%	-$6.61K	0.12%	151
2025 Q3	$250K	Sell	1,078 -2	-0.2%	-$407	0.14%	135
2025 Q2	$200K	Sell	1,080 -17	-2%	-$3.16K	0.12%	142
2025 Q1	$230K	Buy	+1,097	New	+$213K	0.15%	131
2024 Q4	–	Sell	-1,072	Closed	-$212K	–	135
2024 Q3	$212K	Buy	+1,072	New	+$200K	0.14%	128

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

17 Capital Partners's ABBV Position: Q2 2026 in Review

17 Capital Partners reduced its AbbVie (ABBV) stake by 4.5% in Q2 2026, selling an estimated $12.5K and leaving 1,218 shares worth $306K. The position accounts for 0.14% of the portfolio, ranked #155.

17 Capital Partners first reported a position in ABBV in Q3 2024 and has held it in 7 quarters since. 4,224 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

17 Capital Partners held 1,218 shares of AbbVie worth $306K as of Q2 2026.
17 Capital Partners sold 58 AbbVie shares in Q2 2026, an estimated $12.5K.
AbbVie made up 0.14% of 17 Capital Partners's portfolio in Q2 2026, its #155 holding.
17 Capital Partners first reported a position in AbbVie in Q3 2024 and has held it in 7 quarters since.
4,224 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on 17 Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.